ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2016
At a glance
- Drugs Roxadustat (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 25 Jul 2016 Primary endpoint (Haemoglobin level) has been met, as reported in an Astellas Pharma media release.
- 25 Jul 2016 Results published in an Astellas Pharma media release.
- 22 Oct 2014 Last checked against ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History